New antithrombotic strategies: Lessons from clinical trials with glycoprotein IIb/IIIa antagonists and direct thrombin inhibitors

International Journal of Clinical Practice, Supplement

Volumn , Issue 90, 1997, Pages 25-35

  Weitz, Jeffrey ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4;

ARTERY THROMBOSIS; BLOOD CLOTTING; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DILATATION; CORONARY ARTERY THROMBOSIS; HEART MUSCLE ISCHEMIA; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTE;

EID: 0030804097     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (44)

1. Furie B, Furie BL. Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800-806.
2. Harker LA, Mann KG. Thrombosis and Fibrinolysis. In: Fuster V, Verstraete M, Eds. Thrombosis in cardiovascular disorders Philadelphia: Saunders 1992; 1-16.
3. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-1574.
4. Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemostas 1992; 67: 639-643
5. Young E, Cosmi B, Weitz J, Hirsh J. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb Haemost 1993; 70: 625-630.
6. Weitz JI, Hudoba M, Massel D et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391.
7. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci (USA) 1989: 86: 3618-3623
8. Bar-Shavit R, Elbor A, Vlodavsky I. Binding of thrombin to subendothelial matrix: protection and expression of functional properties. J Clin Invest 1989; 84: 1096-1104.
9. Kumar R, Beguin S, Hemker HC. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity. Thromb Haemost 1995; 74: 962-968.
10. Kumar R, Beguin S, Hemker HC. The influence of fibrinogen and fibrin on thrombin generation - evidence for feedback activation of the clotting system by clot-bound thrombin. Thromb Haemost 1994; 72: 713-721.
11. Boneu B, Buchanan MR, Cade JF et al. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo. Thromb Res 1985; 40: 81-89.
12. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988; 71: 831-843.
13. Ruggeri ZM, De Marco L, Gatti L et al. Platelets have more than one binding site for von Willebrand factor. J Clin Invest 1983; 72: 1-12.
14. Pytela R, Pierschbacher MD, Ginsberg MH et al. Platelet membrane glycoprotein IIb/IIIa; member of a family of RGD specific adhesion receptors. Science 1986; 231: 1559-1562.
15. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984; 309: 30-33.
16. Plow EF, D'Souza SE, Ginsberg MH. Ligand binding to GPIIb-IIIa: a status report. Semin Thromb Haemost 1992; 18: 324-332.
17. Kloczewiak M, Timmons S, Hawiger J. Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the gamma chain of human fibrinogen and is not involved in the fibrin polymerization reaction. Thromb Res 1983; 29: 249-255.
18. Kloczewiak M, Timmons S, Lukas TJ, Hawiger J. Platelet receptor recognition site on human fibrinogen: synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. Biochemistry 1984; 23: 1767-1774.
19. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-1559.
20. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoprotein IIb and/or IIIa. J Clin Invest 1983; 72: 325-338.
21. Barker PL, Bullens S, Bunting S et al. Cyclic RGD peptide analogues as antiplatelet antithrombotics. J Med Chem 1992; 35: 2040-2048.
22. Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K. The pharmacology of integrins. Med Res Rev 1994; 14: 195-228.
23. Scarborough RM, Rose JW, Hsu MA. A GPIIb/IIIa-specific integrin antagonist from the venom of Sistrurus M. Barbouri. J Biol Chem 1991; 266: 9359-9362.
24. Stone SR, Maraganore JM. Hirudin interactions with thrombin. In: Berliner LJ, Ed. Thrombin: Structure and Function. New York, NY: Plenum Press, 1992, 219-256.
25. Hotsteenge J, Stone SR, Donella-Deane A, Pinna LA. The effect of substituting phosphotyrosine for sulphotyrosine on the activity of hirudin. Eur J Biochem 1990; 188: 55-59.
26. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-7101.
27. Witting JI, Bourdon P, Brezniak DV et al. Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem J 1992; 283(pt 3): 737-743.
28. Qiu X, Padmanabhan KP, Carperos VE et al. Structure of the hirulog 3-thrombin complex and nature of the S' subsites of substrates and inhibitors. Biochemistry 1992; 31: 11689-11697.
29. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
30. Topol EJ, Califf RM, Weisman HF et al. on behalf of the EPIC Investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months Lancet 1994; 343: 881-886.
31. Aguirre F, Ferguson JJ, Califf RM for the EPIC Investigators. Clinical predictors of bleeding complications in high risk angioplasty: results from the EPIC Study Group (Abstr.). Circulation 1993; 88: I-252.
32. Lincoff AM. EPILOG trial. American College of Cardiology, Orlando, 1996.
33. Simoons ML. CAPTURE trial. American College of Cardiology, Orlando, 1996.
34. Tcheng JE, Lincoff AM, Sigmon KN et al. For the IMPACT II Investigators. Platelet glycoprotein IIb/IIIa inhibition with Integrelin during percutaneous coronary intervention: the IMPACT II trial. Eur Heart J 1996; Eur Soc Cardiol. Amsterdam, 1995.
35. Tcheng JE, Lincoff AM, Sigmon KN et al. For the IMPACT II Investigators. Platelet glycoprotein IIb/IIIa inhibition with Integrelin during percutaneous coronary intervention: the IMPACT II trial. Eur Heart J 1996; Eur Soc Cardiol. Amsterdam, 1995.
36. Serruys PW, Hererman J-PR, Simon R et al.For the HELVETICA Investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995; 333: 757-763.
37. Bittl JA, Strony J, Brinker JA et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333: 764-769.
38. Antman EM for the TIMI 9a Investigators. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI)-9a trial. Circulation 1994; 90: 1624-1630.
39. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. A randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-1637.
40. Ferguson JJ. Meeting Highlights: AHA 68th Scientific Sessions, "TIMI 9b: Heparin versus hirudin as adjunctive therapy for thrombolysis in acute myocardial infarction". Circulation 1996; 93: 843.
41. Armstrong P, Granger C, Califf R et al. GUSTO 2b Trial. American College of Cardiology, Orlando, 1996.
42. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
43. Conforti G, Dominguez-Jimenez C, Zanetti A et al. Human endothelial cells express integrin receptors on the luminal aspect of their membrane. Blood 1992; 80: 437-446.
44. 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 1994; 19: 125-134.